Relmada Therapeutics (RLMD) Set to Announce Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Relmada Therapeutics (NASDAQ:RLMD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.24. During the same period last year, the company earned ($0.84) EPS. On average, analysts expect Relmada Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Relmada Therapeutics Trading Down 2.9 %

NASDAQ:RLMD traded down $0.10 during mid-day trading on Tuesday, hitting $3.32. The stock had a trading volume of 73,824 shares, compared to its average volume of 181,859. Relmada Therapeutics has a twelve month low of $1.88 and a twelve month high of $7.22. The stock has a 50-day simple moving average of $3.26 and a two-hundred day simple moving average of $3.30. The company has a market capitalization of $100.16 million, a PE ratio of -1.15 and a beta of 0.41.

Insider Activity

In related news, Director Charles J. Casamento acquired 13,000 shares of the business's stock in a transaction on Monday, September 9th. The shares were bought at an average price of $2.56 per share, with a total value of $33,280.00. Following the completion of the acquisition, the director now owns 13,000 shares in the company, valued at $33,280. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Charles J. Casamento bought 13,000 shares of Relmada Therapeutics stock in a transaction dated Monday, September 9th. The stock was acquired at an average cost of $2.56 per share, with a total value of $33,280.00. Following the acquisition, the director now owns 13,000 shares of the company's stock, valued at approximately $33,280. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Maged Shenouda bought 24,120 shares of the firm's stock in a transaction that occurred on Wednesday, September 11th. The stock was purchased at an average cost of $2.95 per share, with a total value of $71,154.00. Following the completion of the transaction, the chief financial officer now owns 88,335 shares in the company, valued at approximately $260,588.25. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 152,300 shares of company stock worth $429,655. 18.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, Jefferies Financial Group raised shares of Relmada Therapeutics from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $3.50 to $13.00 in a research report on Tuesday, September 17th.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.